Gary E. Borodic
32Patents
12h-index
7Co-inventors
74Inventor score
Filing activity: Apr 21, 1989 → Jun 22, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5183462A | Controlled administration of chemodenervating pharmaceuticals | Emerging Cross-Sectional Technologies | 80 | Expired |
| US5696077A | Pharmaceutical composition containing botulinum B complex | Emerging Cross-Sectional Technologies | 76 | Expired |
| US5053005A | Chemomodulation of curvature of the juvenile spine | Human Necessities | 67 | Expired |
| US5401243A | Controlled administration of chemodenervating pharmaceuticals | Human Necessities | 57 | Expired |
| US6429189B1 | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases | Emerging Cross-Sectional Technologies | 56 | Expired |
| US5298019A | Controlled administration of chemodenervating pharmaceuticals | Emerging Cross-Sectional Technologies | 43 | Expired |
| US7491403B2 | Pharmaceutical botulinum toxin compositions | Emerging Cross-Sectional Technologies | 26 | Expired |
| US7691394B2 | High-potency botulinum toxin formulations | Human Necessities | 22 | Expired |
| US7537773B1 | Chemodenervating pharmaceutical as anti-inflammatory agent | Human Necessities | 20 | Expired |
| US8691769B2 | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections | Emerging Cross-Sectional Technologies | 13 | Active |
| US8926991B2 | Botulinum toxin and the treatment of primary disorders of mood and affect | Emerging Cross-Sectional Technologies | 13 | Active |
| US7335367B2 | Treatment of chronic chalazion and hordeolum with botulinum toxin | Human Necessities | 12 | Expired |
| US8241640B2 | Pharmaceutical botulinum toxin compositions | Emerging Cross-Sectional Technologies | 11 | Active |
| US9066851B2 | Extended length botulinum toxin formulation for human or mammalian use | Chemistry; Metallurgy | 9 | Active |
| US8192979B2 | Compositions, methods and devices for preparing less painful Botulinum toxin formulations | Human Necessities | 9 | Active |
| US8580745B2 | Composition for therapeutic and cosmetic botulinum toxin | Human Necessities | 8 | Active |
| US7270826B2 | Methods of using Botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion) | Human Necessities | 7 | Expired |
| US7459164B2 | Composition for therapeutic and cosmetic botulinum toxin | Human Necessities | 7 | Expired |
| US9901627B2 | Topical ocular preparation of botulinum toxin for use in ocular surface disease | Chemistry; Metallurgy | 5 | Active |
| US8679486B2 | High-potency botulinum toxin formulations | Human Necessities | 5 | Active |
| US7943152B2 | Treatment of chronic chalazion and hordeolum with botulinum toxin | Human Necessities | 5 | Active |
| US9950042B2 | Extended length botulinum toxin formulation for human or mammalian use | Chemistry; Metallurgy | 4 | Active |
| US7670608B2 | Selection of patients with increased responsiveness to botulinum toxin | Human Necessities | 2 | Expired |
| US8940477B2 | Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action | Physics | 2 | Active |
| US11123411B2 | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.